DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2348)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2026

POLL RESULTS OF THE 2026 ANNUAL GENERAL MEETING

Dawnrays Pharmaceutical (Holdings) Limited (the "Company") announces that at its annual general meeting held on 22 May 2026 (the "AGM"), all proposed resolutions as set out in the notice of AGM dated 24 April 2026 ("AGM Notice") were passed on a poll. Except Mr. Leung Hong Man, who had prior overseas work commitments and was unable to attend the AGM, all directors of the Company namely Ms. Li Kei Ling, Mr. Hung Yung Lai, Mr. Hu Shuo, Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan, attended the AGM in person or by electronic means.

As at the date of the AGM, a total of 1,505,627,000 shares of the Company (the "Shares") were in issue and the holders of which (the "Shareholders") were entitled to attend and vote at the AGM, and the Company did not hold any treasury shares (including any treasury shares held or deposited with Central Clearing and Settlement System). There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the proposed resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"). No Shareholder was required under the Listing Rules to abstain from voting on any of the proposed resolutions at the AGM. No parties have stated their intention in the circular to the Shareholders dated 24 April 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.

The poll results are set out below.

Ordinary Resolutions		Number of Votes (%)[1]		Passed by Shareholders
		For	Against	
1.	To receive and consider the audited consolidated financial statements and the reports of the directors and auditors for the financial year ended 31 December 2025.	1,061,114,211 (99.97%)	268,000 (0.03%)	Yes
2.	To declare a final dividend of HK$0.048 per share for the year ended 31 December 2025.	1,061,382,211 (100.00%)	0 (0.00%)	Yes

* *for identification purpose only*

Ordinary Resolutions		Number of Votes (%)[1]		Passed by Shareholders
		For	Against	
3.	(I). To re-elect Mr. Hung Yung Lai as an executive director of the Company.	1,060,878,211 (99.95%)	504,000 (0.05%)	Yes
	(II). To re-elect Mr. Leung Hong Man as a non-executive director of the Company.	1,060,878,211 (99.95%)	504,000 (0.05%)	Yes
	(III). To re-elect Mr. Hu Shuo as a non-executive director of the Company.	1,060,878,211 (99.95%)	504,000 (0.05%)	Yes
4.	To authorize the board of directors of the Company to fix the remuneration of the directors.	1,061,382,211 (100.00%)	0 (0.00%)	Yes
5.	To re-appoint Ernst & Young as Auditors of the Company and authorize the board of directors to fix their remuneration.	1,061,382,211 (100.00%)	0 (0.00%)	Yes
6.	Ordinary resolution no. 6 set out in the notice of the Annual General Meeting (to grant a general mandate to the directors of the Company to allot, issue and deal with new shares in the Company not exceeding 20% of the total number of issued shares of the Company).[2]	1,005,857,358 (94.77%)	55,524,853 (5.23%)	Yes
7.	Ordinary resolution no. 7 set out in the notice of the Annual General Meeting (to grant a general mandate to the directors of the Company to repurchase shares in the Company not exceeding 10% of the total number of issued shares of the Company).[2]	1,061,382,211 (100.00%)	0 (0.00%)	Yes
8.	Ordinary resolution no. 8 set out in the notice of the Annual General Meeting (to extend the general mandate to the directors of the Company to allot, issue and deal with new shares in the Company by an amount not exceeding the aggregate number of shares of the Company repurchased by the Company).[2]	1,042,901,358 (98.26%)	18,480,853 (1.74%)	Yes

Notes:
1 All percentages are rounded to two decimal places.
2 The full text of Resolutions 6 to 8 is set out in the AGM Notice.

The Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the poll at the AGM.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Pang Kit Ling
Company Secretary

Hong Kong, 22 May 2026

As at the date of this announcement, the Board of the Company comprises two executive directors, namely Ms. Li Kei Ling and Mr. Hung Yung Lai; two non-executive directors, namely Mr. Leung Hong Man and Mr. Hu Shuo; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.